FcResolv® huNOG humanized immune system (HIS) mouse supports long-term engraftment of human lymphoid cells
Taconic Biosciences, a global leader in providing animal models for drug discovery, has expanded the FcResolv® NOG portfolio, the first and only super immunodeficient mouse models lacking residual murine Fc gamma receptors (FcɣRs).
Innate FcɣRs can confound experiments with antibody-based therapeutics containing an Fc domain, causing false positives or false negatives. The knockout of FcɣR function provides improved accuracy in efficacy studies. "Investigators are really responding to this model as a solution to the well-known problem of Fc receptor-mediated interference with therapeutics" said Dr. Michael Seiler, vice president of commercial models at Taconic. "It is gratifying to expand the platform in a way that leverages our expertise in immune system humanization."
The FcResolv® NOG and FcResolv® hIL-15 NOG models were launched in October of 2022. FcResolv® huNOG is the third model in this groundbreaking portfolio; a humanized immune system (HIS) mouse designed for more accurate assessment of antibody-based drugs. These mice have higher average engraftment compared to huNOG mice. The model is made by engrafting hematopoietic stem cells (HSCs) in the FcResolv® NOG strain. Human lymphocytes are present in peripheral blood, bone marrow, and spleen. It is suitable for efficacy studies on antibody-based therapeutics for immuno-oncology, infectious disease, autoimmune disease, and more.
Long-term studies are possible in huNOG mice, with literature reports of stable engraftment and hematopoiesis for one year or more, and similar study windows are expected in this newly released model. However, not all human immune cell types are present, and some cell types may not be completely functional.
The FcResolv® NOG model portfolio currently includes three models:
- FcResolv® NOG, for tumor xenografts using cell lines or patient-derived tumors, engraftment of other normal or pathological human cells and tissues, and immune system humanization studies.
- FcResolv® hIL-15 NOG, which supports engraftment of human NK cells due to human IL-15 cytokine expression, and is suitable for efficacy studies on antibody-based therapeutics with an antibody-dependent cellular cytotoxicity (ADCC) mechanism of action
- FcResolv® huNOG, a HIS mouse suitable for efficacy studies on antibody-based therapeutics for immuno-oncology, infectious disease, autoimmune disease, and more
To learn more about the FcResolv® NOG portfolio, visit www.taconic.com/fcresolv. Or call 1-888-TACONIC (888-822-6642) in the US, +45 70 23 04 05 in Europe, or email info@taconic.com